Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) Insider Daniel Lee Flynn Sells 148,107 Shares

Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) insider Daniel Lee Flynn sold 148,107 shares of the stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $40.92, for a total value of $6,060,538.44. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

DCPH stock traded up $15.95 during mid-day trading on Tuesday, reaching $35.90. The company had a trading volume of 10,854,326 shares, compared to its average volume of 291,452. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.26 and a quick ratio of 7.26. The company has a market cap of $1.44 billion, a P/E ratio of -12.73 and a beta of 2.34. The company has a fifty day moving average of $22.57. Deciphera Pharmaceuticals Inc has a fifty-two week low of $18.55 and a fifty-two week high of $42.99.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last posted its quarterly earnings results on Friday, August 2nd. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.56. The company had revenue of $25.00 million during the quarter, compared to analyst estimates of $20.00 million. Sell-side analysts predict that Deciphera Pharmaceuticals Inc will post -4.29 EPS for the current year.



Hedge funds have recently bought and sold shares of the business. Dimensional Fund Advisors LP acquired a new stake in Deciphera Pharmaceuticals in the 4th quarter valued at about $4,337,000. Geode Capital Management LLC raised its position in shares of Deciphera Pharmaceuticals by 19.4% during the 4th quarter. Geode Capital Management LLC now owns 166,904 shares of the company’s stock worth $3,503,000 after acquiring an additional 27,157 shares in the last quarter. Norges Bank acquired a new stake in shares of Deciphera Pharmaceuticals during the 4th quarter worth about $6,974,000. Marshall Wace North America L.P. raised its position in shares of Deciphera Pharmaceuticals by 4,025.4% during the 1st quarter. Marshall Wace North America L.P. now owns 57,714 shares of the company’s stock worth $1,340,000 after acquiring an additional 56,315 shares in the last quarter. Finally, Bank of America Corp DE raised its position in shares of Deciphera Pharmaceuticals by 1,506.1% during the 4th quarter. Bank of America Corp DE now owns 23,561 shares of the company’s stock worth $494,000 after acquiring an additional 22,094 shares in the last quarter. 59.10% of the stock is currently owned by institutional investors.

Several equities analysts recently issued reports on DCPH shares. Guggenheim increased their target price on Deciphera Pharmaceuticals from $44.00 to $66.00 and gave the stock a “buy” rating in a research note on Tuesday. Zacks Investment Research raised Deciphera Pharmaceuticals from a “sell” rating to a “hold” rating and set a $26.00 target price on the stock in a research note on Monday, August 5th. Piper Jaffray Companies increased their target price on Deciphera Pharmaceuticals from $50.00 to $55.00 and gave the stock an “overweight” rating in a research note on Monday, June 3rd. They noted that the move was a valuation call. ValuEngine raised Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, Deutsche Bank assumed coverage on Deciphera Pharmaceuticals in a research report on Thursday, July 18th. They issued a “buy” rating and a $42.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $43.67.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.

Featured Story: SEC Filing

Insider Buying and Selling by Quarter for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.